Cardiovascular
ICON's cardiovascular trial experience, supported by a global team of experts
A multifaceted risk factor: Addressing obesity's impact across the disease spectrum
With obesity as a risk factor across the disease spectrum, there are several unique considerations and strategies for sponsors and researchers to account for in their approach to development and clinical trials for obesity treatment.
From genomics to the coming of age glycomics
Discover how glycan biomarkers are quickly becoming key elements of cancer, cardiovascular, and gastrointestinal research, setting the stage for a new golden age of epigenetic research and personalised therapeutics.
Mitigating the impact of COVID-19 on cardiovascular trials
COVID-19 has had a significant impact on the conduct of clinical trials and participants. Participants in cardiovascular (CV) trials typically are older, with underlying CV disease or risk factors such as hypertension and diabetes – a population at higher risk of death from COVID-19 if they contract the virus. As a result, these individuals may have heightened concerns about participating in a clinical trial due to the potential for exposure to COVID-19. Discover measures that can be implemented in ongoing trials to ensure the safety of participants, maximise retention and maintain trial integrity
Thriving in Value-Based Healthcare: A guide for cardiovascular medical device manufacturers
In December 2016, the Centers for Medicare & Medicaid Services (CMS) expanded the Bundled Payments for Care Improvement (BPCI) Initiative to include cardiovascular and hip fracture services, taking a major step in the march towards value-based care in the US. Read how can medical device manufacturers sustain growth and successfully navigate this new model?
Reimagining patient-centric clinical trials with the IoMT
Follow a theoretical patient through the entire clinical trial journey – from initial contact for an early study through transition to treatment with an approved product. At each stage, we explore how IoMT can increase clinical development programme efficiency by reducing the burden on patients, caregivers, pharma companies and medical device and diagnostic manufacturers.
Cardiovascular event adjudication during COVID-19 and beyond
In this webinar you will learn more about best practices for cardiovascular event adjudication across drug and device trials, including recent advances in the selection and application of connected devices.
Latest on Cardiovascular, Metabolic, and Circulation
If you would like to receive our Cardiovascular email updates, including the latest on cardiovascular clinical trials, click here to go to our preference centre.
Blogs and media articles relating to cardiovascular and metabolic clinical trials
-
Media article: Diabesity: Implications for treatment and drug development
In this Journal for Clinical Studies’ article, Simon Bruce and Jack Martin discuss the overlap in pathophysiology and treatment of diabetes and obesity along with considerations for streamlining the clinical development of treatments that have therapeutic promise for both conditions.
-
Media article: ICON announces results from survey on obesity-related clinical research
This news article, from Applied Clinical Trials, outlines findings from ICON’s recent survey of over 100 industry professionals on their opinions on future research within the therapeutic area of obesity treatment.
-
Media article: ICON survey stresses combo therapies in obesity care
This news piece from The Clinical Trial Vanguard provides an overview of the findings from ICON’s recent survey of professionals engaged in obesity-related clinical research. It outlines that most respondents believe that obesity therapy trials should measure multiple outcomes due to the overlap between obesity and related comorbidities.
-
Blog: Realising the benefits of bringing decentralised cardiovascular trials to patients
This blog reflects on the success of the first fully decentralised cardiovascular trial during the COVID-19 pandemic and highlights key elements for future trials.
-
Media article: Patient centricity in insulin injection: Using technology to improve self-administration
The following media article will explore how injection technology has made self-administration of insulin easier, and how it will continue to develop into the future.
-
Blog: Navigating cardiovascular clinical trial adjudication during a respiratory pandemic
The COVID-19 pandemic disrupted clinical trials across all indications. For trials that persevered, COVID-19 impacted patient enrollment, participation, and data collection.
-
Media article: Ensuring patient safety and cardiovascular clinical trial integrity during a global pandemic
ICON experts share insights on ensuring patient safety and cardiovascular clinical trial integrity during the COVID-19 pandemic.
-
Blog: Digital health technologies: Implementing innovation in cardiovascular studies during COVID-19
ICON experts discuss how the COVID-19 pandemic has led to the implementation of more efficient cardiovascular (CV) trial designs and operational execution.
Cardiovascular clinical trials services at ICON
ICON has over 25 years' experience conducting cardiovascular trials, with particular emphasis on key cardiovascular/metabolic indications: heart failure, lipid disorders, diabetes, renal insufficiency and renal transplant, arrhythmia, and rare diseases.